UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis

Gosling, RD; Uiso, LO; Sam, NE; Bongard, E; Kanduma, EG; Nyindo, M; Morris, RW; (2003) The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. AM J RESP CRIT CARE , 168 (11) 1342 - 1345. 10.1164/rccm.200305-682OC. Green open access

[img]
Preview
PDF
Bactericidal_activity_of_Moxifloxacin_in_patients_iwth_pulmonary_tuberculosis.pdf

Download (72kB)

Abstract

Patients in whom acid-fast bacilli smear-positive pulmonary tuberculosis was newly diagnosed were randomized to receive 400 mg moxifloxacin, 300 mg isonaizid, or 600 mg rifampin daily for 5 days. Sixteen-hour overnight sputa collections were made for the 2 days before and for 5 days of monotherapy. Bactericidal activity was estimated by the time taken to kill 50% of viable bacilli (vt(50)) and the fall in sputum viable count during the first 2 days designated as the early bactericidal activity (EBA). The mean vt(50) of moxifloxacin was 0.88 days (95% confidence interval [Cl], 0.43-1.33 days) and the mean EBA was 0.53 (95% CI 0.28-0.79). For the isoniazid group, the mean vt(50) was 0.46 days (95% Cl, 0.31-0.61 days) and the mean EBA was 0.77 (95% Cl, 0.54-1.00). For rifampin, the mean vt(50) was 0.71 days (95% Cl, 0.48-0.95 days) and the mean EBA was 0.28 (95% Cl, 0.15-0.41). Using the EBA method, isoniazid was significantly more active than rifampin (p < 0.01) but not moxifloxacin. Using the vt(50) method, isoniazid was more active than both rifampin and moxifloxacin (p = 0.03). Moxifloxacin has an activity similar to rifampin in human subjects with pulmonary tuberculosis, suggesting that it should undergo further assessment as part of a short course regimen for the treatment of drug-susceptible tuberculosis.

Type: Article
Title: The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis
Open access status: An open access version is available from UCL Discovery
DOI: 10.1164/rccm.200305-682OC
Keywords: clinical trials, Africa, tuberculosis, quinolone, SPUTUM VIABLE COUNTS, IN-VIVO ACTIVITIES, ANTITUBERCULOSIS DRUGS, MYCOBACTERIUM-TUBERCULOSIS, STERILIZING ACTIVITIES, CIPROFLOXACIN, VITRO, FLUOROQUINOLONES, RIFABUTIN
UCL classification: UCL
URI: https://discovery.ucl.ac.uk/id/eprint/286
Downloads since deposit
393Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item